Pipeline Overview

Complementary platforms that act alone or in combination with other treatments to treat cancer and chronic diseases.

CyNRGY Platform

First-in-Class small molecules with lead candidate RRx-001

RRx-001 in Small Cell Lung Cancer | Phase 3

3L+ SCLC “REPLATINUM” Phase 3 study enrolling in US and China
Sensitizing tumors to respond to platinum-based chemotherapy.

View Clinical Trial

eLoop Administration Device | Phase 3

Proprietary device designed for optimized IV delivery of RRx-001.

RRx-001 Pilot Studies | Preclinical

Programs include Liver Cancer and Leukemia.

RRx-001 in radiation protection | Phase 2

As a pretreatment in 1L Head & Neck Cancer Prevention of radiation induced oral mucositis.

RRx-001 Inflammasome Inhibition | Preclinical

Chronic diseases linked to uncontrolled or dysfunctional inflammation regulated by the inflammasome.

AdAPT Platform

Cancer Targeting Viruses with lead candidate AdAPT-001

AdAPT-001 “TGFβ trap” | Phase 1

“BETA PRIME” Phase 1 study of the AdAPT cancer-targeting virus technology with TGFβ neutralizing enhancement for immune activation against cancer.

View Clinical Trial

AdAPT-PSV “Personalized” | Phase 1

Patient specific cancer mutations (neoantigens) are added to our cancer targeting virus.

AdAPT-002 (undisclosed) | Preclinical

The next AdAPT Platform cancer targeting virus.

AdAPT Nanoparticle Encapsulation | Preclinical

Optimization of AdAPT Platform treatments for improved delivery and performance.

pulsing dot

Clinical Trials

Our currently active clinical trials.

Phase 3

Study: REPLATINUM: A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Carcinoma

Conditions: Small Cell Lung Cancer

Interventions: Drug: RRx-001; Drug: Cisplatin/carboplatin

ClinicalTrials.gov Identifier: NCT03699956

Phase 1

Study: BETA PRIME: A Phase I, First in Human, Study to Evaluate the Safety and Tolerability of AdAPT-001 in Subjects With Refractory Solid Tumors. 3 + 3 dose escalation safety run-in (Part 1) followed by a dose expansion single-agent (Part 2) and completing with AdAPT-001 combined with an immune checkpoint inhibitor (Part 3).

Conditions: Solid Tumors, palpable / easily accessible for needle injection

Interventions: Drug: AdAPT-001

ClinicalTrials.gov Identifier: NCT04673942

Phase 1

Study: PIRATE: RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors

Conditions: Brain Tumor, Recurrent; Brain Tumor, Pediatric; Central Nervous System Neoplasms; Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Drug: RRx-001; Drug: Temozolomide; Drug: Irinotecan

ClinicalTrials.gov Identifier: NCT04525014